Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 17.15 | 27.65 | 6.97 | 18.09 | -193.11 |
| Net Profit | 18.70 | 27.14 | 37.45 | 19.76 | -187.25 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -92.86 | -54.41 | -134.80 | -95.14 | -111.61 |
| Return on Capital
| -92.86 | -26.99 | -- | -95.14 | -111.61 |
| Return on Assets
| -84.31 | -353.65 | -101.22 | -84.50 | -100.89 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
--
|
-95.14
|
-111.61
|
-71.83
|
-72.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-134.80
Lower than Peers by 94.40
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
-134.80
|
-95.14
|
-111.61
|
-71.83
|
-82.78
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-101.22
Lower than Peers by 70.24
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
-101.22
|
-84.50
|
-100.89
|
-67.56
|
-65.09
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Growth
6.97
Higher than Peers by 7.77
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
6.97
|
57.00
|
21.26
|
-56.33
|
-359.28
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
37.45
Higher than Peers by 44.75
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
37.45
|
56.52
|
23.68
|
-54.26
|
-273.68
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.27
Higher than Peers by 1.46
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
7.27
|
11.62
|
8.02
|
12.37
|
20.55
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
7.27
Higher than Peers by 1.57
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
7.27
|
--
|
--
|
--
|
20.55
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-114.76
Lower than Peers by 112.67
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
-114.76
|
--
|
-182.52
|
-2,757.57
|
-26.04
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
3.33
Lower than Peers by 1.86
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
3.33
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.22
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
0.22
|
-21.98
|
0.57
|
0.90
|
2.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
0
Lower than Peers by 146
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
|
0
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|